parkinson-tratamiento-con-celulas-madre-1280x720

Parkinson’s disease is the second most common neurodegenerative disease caused by the loss of midbrain neurons that synthesize the neurotransmitter dopamine. This neurotransmitter is responsible of the
transmission of motor signals to the brain. Clinically, tremor, stiffness, and slow voluntary movements characterize Parkinson’s disease.

Current therapies are based on the use of dopamine precursors and the reduction of dopamine metabolism, however it does not modify the disease progression but only improve momentarily the symptoms.

Cell replacement therapies with stem cells are a very promising therapy, as it has been demonstrated in both animal studies and clinical practice. When dopamine is reintroduced in the central nervous system, decreases or reverses symptoms, this means that if stem cells can be induced into dopamine producer neurons and afterwards transplanted in affected zones, they could replace degenerated cells and recover its functionality.

Induced pluripotent stem cells derived from somatic cells of patients represent a powerful tool for biomedical research and may provide a source for replacement therapies. Studies show that fibroblasts from patients with idiopathic Parkinson’s disease can be efficiently reprogrammed and subsequently differentiated into dopaminergic neurons.

The intranasal delivery, targeting and treatment technology can make stem cell treatments practical for central nervous system disorders by eliminating the need for invasive neurosurgical implantation of cells and by eliminating the need for intravenous delivery that disperses cells throughout the body resulting in unwanted systemic exposure. This delivery and treatment method can facilitate the development of stem cell and genetically-engineered cell therapies for Parkinson’s disease.

Treatment with mesenchymal stem cells improve behavioral outcomes, improve motor functions and are neuroprotective in Parkinson’s disease models, analyses suggest that mesenchymal stem cells could be considered for early-stage clinical trials in the treatment of Parkinson’s disease.

Stem Cells transplant Institute aims to be a pioneer entity in stem cells therapies, offering innovating and secure options for patients who does not respond to conventional treatment or patients that are looking for treatments that actually change de course of the disease.

For more information

Send us your messages

Your Name (required)

Your Email (required)

Phone

Subject

Your Message